| Hans-Günter Meyer-Thompson | International
Why pharma firms are betting billions on psychedelic drugs despite setbacks
Why pharma firms are betting billions on psychedelic drugs despite setbacks
Regulatory pushback stalled the field. But researchers are optimistic about mind-altering drugs as potential treatments for depression and mood disorders. (Nature, USA, 27.10.2026)